MBQ-167
is a novel, small-molecule dual inhibitor of Rac and Cdc42,
small GTPases that are involved in cytoskeletal organization, cell
cycle progression, and cell migration. In an in vivo mouse model, MBQ-167 has been shown to significantly reduce mammary
tumor growth and metastasis and is currently undergoing preclinical
studies for the treatment of metastatic cancer. To date, no solubility
data have been reported for this compound. For this reason, the present
study aims to determine the solubility of this compound in eight neat
solvents (acetonitrile, 1-butanol, 2-butanol, ethanol, ethyl acetate,
methanol, 1-propanol, and 2-propanol) and two binary solvent mixtures
[ethyl acetate (2) + heptane (3) and ethanol (2) + water (3)] between
the temperatures of 278.15 and 333.15 K. The results obtained employing
the polythermal method show that the solubility of MBQ-167 increases
with an increase in temperature in all neat solvents used within this
study. Moreover, in the two binary solvent mixtures, the solubility
of this compound increases with increasing temperature and decreases
with an increasing mass fraction of the antisolvent (heptane or water).
The experimental solubility data were correlated using the modified
Apelblat and λh model equations. The predicted solubility data
acquired from the Apelblat and λh model equations correlate
well with the experimental solubility data as indicated by the low
ARD % (≤1.8304 and ≤6.5366, respectively). No solvent-mediated
polymorphic phase transitions were observed while performing the solubility
studies, and no other solid forms were detected after the recrystallization
in the solvents and solvent mixtures. The solubility data determined
here can offer pathways to develop pharmaceutical crystallization
processes that can further the translation of MBQ-167 into a clinical
setting.